INTRODUCTION AND OBJECTIVES: Sex cord-gonadal stromal tumors (SCGS) of the testicle, primarily made up of Leydig cell and Sertoli cell tumors, are rare testicular neoplasms. Single institutional studies suggest that metastases are rare and survival excellent. We utilized the SEER database to characterize risks of metastasis in patients with SCGS tumors.
METHODS: We interrogated the SEER database from 1973 to 2010 to identify all Leydig cell (code -86503) and Sertoli cell (code -86403) tumors among male patients. Data collected and analyzed included patient age and race; SEER stage including limited to primary site (Localized), the presence of disease in retroperitoneal lymph nodes (Regional) and distant metastases (Distant); as well as cancer-specific and overall survival. RESULTS: We identified 53 patients with Leydig cell tumors and 23 with Sertoli cell tumors. Sertoli cell tumors were fairly evenly distributed overall all age groups while Leydig cell tumors were concentrated among ages 30-59. Using SEER extent of disease, 79% were found to be Localized and 21% Distant on initial presentation with equal distribution among patients with Leydig and Sertoli cell tumors. Median survival of patients presenting with metastases was 27 months. Patients with apparently Localized disease had a 13% chance of developing metastases at a median of 17 months. Patients with SCGS tumors of the testicle whether localized or metastatic had a significantly poorer survival compared to patients with germ cell tumors.
CONCLUSIONS: This study represents the largest analysis of outcomes for patients with SCGS tumors. These neoplasms have a high risk of presenting with metastasis (20%) than previously recognized as as well as a significant risk (13%) of patients with Localized tumor developing a recurrence. Patients with metastatic SCGS tumors are at higher risk of dying from their disease than patients with metastatic germ cell neoplasms likely due to inherent resistance to radiation and chemotherapy. RESULTS: FSEs were performed on 142 testicular lesions during inguinal exploration of the affected testis. Germ cell tumors (GCT) and non-GCT pathologies were correctly identified in 106 cases (74.6%, 46 non-seminomas, 60 seminomas) and 35 cases (24.6%), respectively. One case was incorrectly classified as non-malignant hypocellular nodule on FSE. However, final pathology revealed a seminoma. The patient underwent a secondary inguinal orchiectomy and remains disease-free 6 years post orchiectomy under active surveillance. No patient underwent unnecessary orchiectomy due to an incorrectly classified testicular GCT. According to our data, FSE has a sensitivity of 99% (95% CI 95%-100%), a specificity of 100% (95% CI 85%-100%), a positive predictive value of 100% (95% CI 95%-100%) and a negative predictive value of 97% (95% CI 85%-100%).
CONCLUSIONS: FSE is a useful diagnostic tool, which reliably predicts the presence or absence of GCT and thus is helpful to guide intraoperative management of testicular lesions particularly in patients with inconclusive preoperative results (i.e. negative tumor markers). To minimize the rate of unnecessary orchiectomies, these patients should only be treated in institutions where FSE is available. 197, No. 4S, Supplement, Monday, May 15, 2017 THE JOURNAL OF UROLOGY â e1083
